文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

CPX-351 在新诊断儿童继发性髓系恶性肿瘤中诱导缓解

CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies.
PubMed 文献 · Blood Adv · 2022-01-01

该研究报告 7 例年轻患者(6 例新诊断继发性 MDS/AML,1 例原发性 MDS/AML)均接受 CPX-351 治疗,中位诊断年龄 17 岁。患者接受 1 至 3 周期 CPX-351(阿糖胞苷 100 mg/m2 加柔红霉素 44 mg/m2,第 1、3、5 天),均获完全形态学缓解,无 overt 毒性或治疗相关死亡。6 例在 HCT 后 0.5 至 3.3 年无白血病生存,1 例 HCT 前疾病进展死亡。

要点

  • CPX-351 在儿童继发性 MDS/AML 中可诱导完全形态学缓解且耐受良好。
  • 7 例中 6 例 HCT 后 0.5 至 3.3 年无白血病生存。
  • 1 例因个体化治疗加用 FLT3 抑制剂。

核心结论

  • CPX-351 是儿童继发性 MDS/AML 降细胞治疗的有效且耐受良好的方案,值得前瞻性研究。

研究设计与样本

  • 回顾性报告 7 例年轻患者(6 例新诊断 sMDS/AML,1 例原发性 MDS/AML)均接受 CPX-351 治疗。
  • 中位诊断年龄 17 岁(范围 13-23 岁)。

主要发现

  • 患者接受 1 至 3 周期 CPX-351(阿糖胞苷 100 mg/m2 加柔红霉素 44 mg/m2,第 1、3、5 天),均获完全形态学缓解,无 overt 毒性或治疗相关死亡。
  • 6 例在 HCT 后 0.5 至 3.3 年无白血病生存,1 例 HCT 前疾病进展死亡。
  • 1 例患者因个体化治疗加用 FLT3 抑制剂。

关键数值与推荐

  • CPX-351 为脂质体阿糖胞苷与柔红霉素固定 5:1 摩尔比。
  • 给药方案:阿糖胞苷 100 mg/m2 加柔红霉素 44 mg/m2,第 1、3、5 天。

临床怎么用

  • CPX-351 可作为儿童继发性 MDS/AML 的降细胞治疗选择,为 HCT 桥接。

局限性

  • 样本量小(7 例),为回顾性报告,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary myelodysplastic syndromes and acute myeloid leukemia (sMDS/AML) are rare in children and adolescents and have a dismal prognosis. The mainstay therapy is hematopoietic cell transplantation (HCT), but there has been no innovation in cytoreductive regimens. CP X-351, a fixed 5:1 molar ratio of liposomal cytarabine to daunorubicin, has shown favorable safety and efficacy in elderly individuals with secondary AML and children with relapsed de novo AML. We report the outcomes of 7 young patients (6 with newly diagnosed sMDS/AML and 1 with primary MDS/AML) uniformly treated with CP X-351. Five patients had previously received chemotherapy for osteosarcoma, Ewing sarcoma, neuroblastoma, or T-cell acute lymphoblastic leukemia; 1 had predisposing genomic instability disorder (Cornelia de Lange syndrome) and 1 had MDS-related AML and multiorgan failure. The median age at diagnosis of myeloid malignancy was 17 years (range, 13-23 years). Patients received 1 to 3 cycles of CP X-351 (cytarabine 100 mg/m2 plus daunorubicin 44 mg/m2) on days 1, 3, and 5, resulting in complete morphologic remission without overt toxicity or treatment-related mortality. This approach allowed for adding an FLT3 inhibitor as individualized therapy in 1 patient. Six patients were alive and leukemia-free at 0.5 to 3.3 years after HCT. One patient died as a result of disease progression before HCT. To summarize, CP X-351 is an effective and well-tolerated regimen for cytoreduction in pediatric sMDS/AML that warrants prospective studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hu Y, Caldwell KJ, Onciu M, et al. CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies. Blood Adv. 2022. PMID: 34710216. doi:10.1182/bloodadvances.2021006139

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。